Who Owns NRX Pharmaceuticals Stock?
NASDAQ: NRXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 27.13%
- Held by insiders
- 4.12%
- Institutional holders
- 53
- Institutions 27.1%
- Insiders 4.1%
- Public and other 68.8%
Who owns NRX Pharmaceuticals stock?
Institutional investors own about 27.1% of NRX Pharmaceuticals's shares, spread across 53 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 4.12% of NRXP.
The largest institutional holders are B Group, Inc. (9.45%), Vanguard Capital Management LLC (3.74%) and Ameriprise Financial, Inc. (2.15%). Together, the top 10 institutions control 23.8% of shares outstanding. In their latest filings, 10 of the top 10 institutions increased their NRXP positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NRXP
| Institution | Shares | % Held | Change |
|---|---|---|---|
| B Group, Inc. | 4.09M | 9.45% | +36.4% |
| Vanguard Capital Management LLC | 1.62M | 3.74% | +39.5% |
| Ameriprise Financial, Inc. | 928.73K | 2.15% | +100.0% |
| Balyasny Asset Management LP | 893.86K | 2.06% | +100.0% |
| Citadel Advisors Llc | 680.04K | 1.57% | +100.0% |
| AdvisorShares Investments, LLC | 659.02K | 1.52% | +56.7% |
| Commonwealth Equity Services, LLC | 454.42K | 1.05% | +14.3% |
| UBS Group AG | 423.12K | 0.98% | +1577.2% |
| Geode Capital Management, LLC | 314.66K | 0.73% | +1.5% |
| Blackrock Inc. | 220.46K | 0.51% | +122.7% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NRXP
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.27M | 2.93% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 805.07K | 1.86% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 291.39K | 0.67% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 144.66K | 0.33% |
| iShares Trust-iShares Micro-Cap ETF | 104.28K | 0.24% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 50.45K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 38.41K | 0.09% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 21.98K | 0.05% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 21.72K | 0.05% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 15.46K | 0.04% |
Frequently asked questions
Who is the largest shareholder of NRX Pharmaceuticals?
B Group, Inc. is the largest institutional shareholder of NRXP, owning 9.45% of shares outstanding (4.09M shares) as of its latest 13F filing.
What percentage of NRX Pharmaceuticals is owned by institutions?
Institutions own about 27.1% of NRXP shares and 28.3% of the public float.
How much of NRX Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 4.12% of NRXP shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.